Hangzhou Bio-Sincerity Pharma-TechLtd Future Growth
Future criteria checks 5/6
Hangzhou Bio-Sincerity Pharma-TechLtd is forecast to grow earnings and revenue by 37.6% and 29.9% per annum respectively. EPS is expected to grow by 37.5% per annum. Return on equity is forecast to be 15% in 3 years.
Key information
37.6%
Earnings growth rate
37.5%
EPS growth rate
| Life Sciences earnings growth | 34.7% |
| Revenue growth rate | 29.9% |
| Future return on equity | 15.0% |
| Analyst coverage | Low |
| Last updated | 16 Aug 2024 |
Recent future growth updates
No updates
Recent updates
We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability
Nov 04
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward
Sep 30Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower
Jul 24Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)
Apr 29Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?
Mar 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,134 | 598 | -120 | 713 | 4 |
| 12/31/2025 | 1,687 | 463 | -269 | 502 | 4 |
| 12/31/2024 | 1,315 | 357 | -135 | 488 | 4 |
| 9/30/2024 | 1,025 | 212 | -693 | -126 | N/A |
| 6/30/2024 | 1,119 | 287 | -647 | -5 | N/A |
| 3/31/2024 | 1,072 | 287 | -751 | -28 | N/A |
| 12/31/2023 | 1,017 | 272 | -598 | 90 | N/A |
| 9/30/2023 | 900 | 250 | -520 | 135 | N/A |
| 6/30/2023 | 786 | 229 | -531 | 154 | N/A |
| 3/31/2023 | 673 | 210 | -388 | 289 | N/A |
| 1/1/2023 | 607 | 194 | -332 | 259 | N/A |
| 9/30/2022 | 573 | 192 | -319 | 241 | N/A |
| 6/30/2022 | 479 | 155 | -194 | 224 | N/A |
| 3/31/2022 | 425 | 126 | -178 | 117 | N/A |
| 12/31/2021 | 374 | 111 | -103 | 145 | N/A |
| 9/30/2021 | 304 | 101 | -167 | 100 | N/A |
| 6/30/2021 | 267 | 85 | -204 | 80 | N/A |
| 3/31/2021 | 211 | 55 | -229 | 49 | N/A |
| 12/31/2020 | 207 | 57 | -201 | 54 | N/A |
| 12/31/2019 | 156 | 44 | -35 | 71 | N/A |
| 12/31/2018 | 82 | 11 | 26 | 45 | N/A |
| 12/31/2017 | 26 | -7 | N/A | 11 | N/A |
| 6/30/2017 | 30 | 8 | N/A | 11 | N/A |
| 3/31/2017 | 27 | 5 | N/A | 6 | N/A |
| 12/31/2016 | 24 | 3 | N/A | 2 | N/A |
| 9/30/2016 | 21 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 16 | -1 | N/A | 5 | N/A |
| 3/31/2016 | 16 | 2 | N/A | 4 | N/A |
| 1/1/2016 | 16 | 5 | N/A | 3 | N/A |
| 12/31/2014 | 6 | -2 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301096's forecast earnings growth (37.6% per year) is above the savings rate (2.9%).
Earnings vs Market: 301096's earnings (37.6% per year) are forecast to grow faster than the CN market (25.8% per year).
High Growth Earnings: 301096's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301096's revenue (29.9% per year) is forecast to grow faster than the CN market (14% per year).
High Growth Revenue: 301096's revenue (29.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301096's Return on Equity is forecast to be low in 3 years time (15%).